MRUS trades 1.5% above Wall Street's consensus target of $88.69.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MRUS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 22 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Merus N.V. (MRUS) has a Wall Street consensus price target of $88.69, based on estimates from 22 covering analysts. With the stock currently trading at $90.00, this represents a potential downside of -1.5%. The company has a market capitalization of $6.83B.
Analyst price targets range from a low of $30.00 to a high of $99.00, representing a 78% spread in expectations. The median target of $97.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 10 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MRUS trades at a trailing P/E of -26.9x. Analysts expect EPS to grow -11.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ZYMEZymeworks Inc. | $2.0B | $27.50 | $41.00 | +49.1% | Buy | 18.9x | 22 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 AGENAgenus Inc. | $350M | $8.40 | $25.00 | +197.6% | Buy | 10.8x | 11 |
 FATEFate Therapeutics, Inc. | $283M | $2.43 | $5.63 | +131.7% | Buy | — | 31 |
 XNCRXencor, Inc. | $1.8B | $24.26 | $34.40 | +41.8% | Buy | — | 28 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
 ABBVAbbVie Inc. | $468.7B | $265.30 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 RGENRepligen Corporation | $10.4B | $184.53 | $162.43 | -12.0% | Buy | 89.5x | 24 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 INCYIncyte Corporation | $25.3B | $124.64 | $130.07 | +4.4% | Buy | 33.1x | 44 |
Quick answers to the most common questions about buying MRUS stock.
Wall Street's consensus price target for MRUS is $88.69, -1.5% from its current price of $90. The below-market target from 22 analysts suggests limited near-term appreciation.
MRUS has a consensus rating of "Hold" based on 22 Wall Street analysts. The rating breakdown is mixed, with 12 Hold ratings making up the largest segment. The consensus 12-month price target of $88.69 implies -1.5% downside from current levels.
MRUS's current price is $90 with a consensus target of $88.69 (-1.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $99 for MRUS, while the most conservative target is $30. The consensus of $88.69 represents the median expectation. These targets typically reflect 12-month expectations.
MRUS is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 12 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MRUS stock forecast based on 22 Wall Street analysts shows a consensus price target of $88.69, with estimates ranging from $30 (bear case) to $99 (bull case). The median consensus rating is "Hold".
Analysts are cautious on MRUS, with 0 Sell ratings and a price target of $88.69 (-1.5% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MRUS analyst price targets range from $30 to $99, a 78% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $88.69 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.